All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Targeting ROR-1 with zilovertamab in MCL and CLL
Bookmark this article
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about the benefits of targeting ROR-1 with zilovertamab in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Targeting ROR-1 with zilovertamab in MCL and CLL
Lee provides a summary of the latest safety and efficacy data from a phase I/II study of zilovertamab + ibrutinib in relapsed/refractory CLL and MCL, outlining the encouraging progression-free survival rates seen even in high-risk patients with TP53 alterations. Lee then discusses plans for further study of the apparent synergy between zilovertamab and ibrutinib and a phase III study of zilovertamab + ibrutinib versus ibrutinib + placebo in R/R MCL to validate these findings
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
60 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox